Those diagnosed with epilepsy are at risk for early death. Early deaths caused by epilepsy are often due to accidents, suicide, or assaults. This disease can have a significant impact on social and economic conditions. The social stigma associated with epilepsy is often worse than the seizures themselves, limiting people’s willingness to seek treatment. Fortunately, there are a number of ways to manage the symptoms of epilepsy.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4339
Treatments for epilepsy may include a combination of medications, including anticonvulsants. Some are available in tablet form; others are liquid or injections. Despite the risks associated with some medications, children with epilepsy can often take part in mainstream schooling and activities. Some will even be able to get jobs after being diagnosed. The most common type of seizure is a general onset seizure, which affects a large network of brain cells on both sides of the brain at the same time. Seizures can also last for minutes or even weeks. A generalized seizure can be characterized by several different types, which are more common in children and elderly adults.
Epileptic Seizures Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
The demand for epileptic seizures treatment remained same during COVID-19 pandemic, as it is observed that epilepsy and COVID-19 infection does not have a direct connection. According to the International League against Epilepsy, there is no direct evidence that the coronavirus infection can directly cause epilepsy. However, like most of the infections can cause high fever, breathing difficulties, and other problems with normal functioning, being infected can result in a person who is susceptible to epilepsy, might suffer breakthrough episodes. Although, disruption in the supply of drugs have slightly impacted the epileptic seizures treatment market negatively.
The epileptic seizures treatment market is estimated to be valued at US$ 3.0 billion in 2020 and is expected to exhibit a CAGR of 5.4% during the forecast period (2020-2027).
Increasing clinical trials and growing drug approvals & launches are projected to boost growth of the epileptic seizures treatment market
Growing clinical trials for new drug for the treatment of epileptic seizures is projected to accelerate the epileptic seizures treatment market growth over the forecast period. For instance, in January 2019, Xenon Pharmaceuticals Inc. in collaboration with NCGS, Inc. initiated a clinical study on the drug, XEN1101 for the treatment of focal epilepsy. The trial aims to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy. In this trial, 300 patients are involved, who are being treated with XEN1101 and placebo capsules. This clinical trial is in phase 2 and is expected to complete in June 2022.
Furthermore, growing drug approvals and launches for the treatment of epileptic seizures is projected to drive the global epileptic seizures treatment market growth. For instance, Eisai Co., Ltd. announced that they received a New Drug Approval for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. Hence, such approvals are projected to positively impact the global epileptic seizures treatment market growth.
Epileptic Seizures Treatment Market – Restraints
Anti-epileptic drugs exhibit mild or adverse neurological side effects occasionally, however they can be fatal. The adverse reactions and risks vary with each medication. Majority of antiepileptic drugs have the potential to cause an allergic reaction. These drugs indirectly increase the risk of conditions such as aggressive behavior and depression. In pregnant women, anti-epileptic drugs can also harm the fetus. According to the Journal of Family Practice the side effects of anti-epileptic drugs include – Phenytoin causes a pattern of defects collectively called the Fetal Hydantoin Syndrome (FHS) characterized by variable degrees of hypoplasia and ossification of the distal phalanges and craniofacial abnormalities. Additionally, anticonvulsants, particularly hydantoins and barbiturates are associated with hemorrhagic diseases in newborns. Thus, such severe side effects are projected to restrict the epileptic seizures treatment market growth over the forecast period.
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4339
Epileptic Seizures Treatment Market – Regional Analysis
North America is projected to hold leading position in the global epileptic seizures treatment market in 2020 owing to growing product launches and product approvals by regulatory authorities in the region. For instance, in November 2019, SK Life Science, Inc. announced that the U.S. Food and Drug Administration (FDA) approved XCOPRI (cenobamate tablets) for the treatment of partial-onset seizures in adults. Similarly, in August 2019, Dr. Reddy’s Laboratories launched generic anti-epileptic Vigabatrin powder for oral solution in the U.S. market.
Moreover, Asia Pacific epileptic seizures treatment market is projected to witness significant growth during the forecast period, due to growing agreements between the key players for supply of anti-epileptic drugs in Asia Pacific region. For instance, in December 2017, Hydroponics Company entered into agreement with BOL Pharma to supply BOL Pharma’s medicinal cannabis products in Australia. BOL Pharma’s medicinal cannabis products are intended to be used for the treatment of patients suffering from epilepsy and other neurological disorders.
Epileptic Seizures Treatment Market – Competitive Landscape
Key players operating in the global epileptic seizures treatment market include Novartis AG, GlaxoSmithKline Plc, Johnson & Johnson Service, Inc., Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Sanofi S.A., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., Abbott Laboratories, Sumitomo Dainippon Pharma Co., Ltd., GW Pharmaceuticals Plc, Marinus Pharmaceuticals, Inc., H. Lundbeck A/S, and Takeda Pharmaceutical Co., Ltd.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4339
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Epileptic Seizures Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Epileptic Seizures Treatment Industry Impact
Chapter 2 Global Epileptic Seizures Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Epileptic Seizures Treatment (Volume and Value) by Type
2.3 Global Epileptic Seizures Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Epileptic Seizures Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Epileptic Seizures Treatment Market Analysis
Chapter 6 East Asia Epileptic Seizures Treatment Market Analysis
Chapter 7 Europe Epileptic Seizures Treatment Market Analysis
Chapter 8 South Asia Epileptic Seizures Treatment Market Analysis
Chapter 9 Southeast Asia Epileptic Seizures Treatment Market Analysis
Chapter 10 Middle East Epileptic Seizures Treatment Market Analysis
Chapter 11 Africa Epileptic Seizures Treatment Market Analysis
Chapter 12 Oceania Epileptic Seizures Treatment Market Analysis
Chapter 13 South America Epileptic Seizures Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Epileptic Seizures Treatment Business
Chapter 15 Global Epileptic Seizures Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
View Press Release: https://www.coherentmarketinsights.com/press-release/epileptic-seizures-treatment-market-3599
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027